Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on the development of the drug in ...

Having lupus may increase your risk of food allergies. And certain foods may trigger lupus flares. Learn more.

known as lupus nephritis (LN). Credit: SciePro via Shutterstock. Clinical stage biopharma company Kezar Life Sciences is discontinuing its LN clinical programme following the death of four patients.

2 Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China 3 University of Chinese Academy of Sciences, Beijing, ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

Systemic lupus is the most common form of lupus—it’s what most people mean when they refer to “lupus.” Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...

Walk to End Lupus Now ™ events provide all people affected by Lupus and their families the opportunity to come together for one unified purpose — to end Lupus. Join the Lupus Foundation of America and ...

Roche is also running trials of crovalimab for other diseases, including aHUS, sickle cell disease, and lupus nephritis. Sage Therapeutics has launched another round of layoffs as it deals with ...

CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor ...